<DOC>
	<DOCNO>NCT02739711</DOCNO>
	<brief_summary>Aim study examine effect glycoprotein IIb/IIIa inhibitor reperfusion success assess cardiac magnetic resonance imaging patient myocardial infarction angiographic evidence no-reflow .</brief_summary>
	<brief_title>Glycoprotein IIb/IIIa Inhibitors Versus Standard Therapy Patients With Myocardial Infarction No-reflow</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<criteria>STelevation myocardial infarction nonSTelevation myocardial infarction &lt; 48 h symptom onset Angiographic evidence noreflow ( Thrombolysis Myocardial Infarctionflow grade ≤2 ) primary percutaneous coronary intervention Age ≥18 year Informed consent STelevation myocardial infarction nonSTelevation myocardial infarction patient Thrombolysis Myocardial Infarctionflow 3 primary percutaneous coronary intervention Age ≤18 year Known pregnancy , breastfeed intend become pregnant study period Contraindication treatment platelet inhibitor Known allergy glycoprotein IIb/IIIa inhibitor , aspirin , heparin Active peptic gastric duodenal ulcer History major surgery ( include intracranial intraspinal ) &lt; 4 week Active bleed bleed diathesis Stroke &lt; 2 year ( ischemic hemorrhagic ) Known coagulation defect relevant thrombocytopenia Arteriovenous malformation aneurysm Severe liver insufficiency Renal insufficiency require dialysis Uncontrolled hypertension Hypertensive retinopathy Vasculitis Fibrinolysis &lt; 12 hour Contraindication cardiac magnetic resonance imaging study entry Patients without informed consent Participation another trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>